Birthplace
İSTANBUL
Languages
ENGLISH
Medical Areas of Interest
- Breast Cancer
- Gynecological Cancers
- Lung Cancer
- Colon Cancer
- Stomach Cancer
- Prostate Cancer
- Bladder Cancer
- Pancreatic Cancer
- All Types of Cancer
Highlights
She was born in Istanbul in 1986. Between 1997 and 2005, she studied at Istanbul High School (Istanbul Erkek Lisesi), one of the country’s long-established and prestigious educational institutions; she completed a dual-diploma program within the German education system and qualified for the Abitur diploma.
She graduated from Istanbul University, Istanbul Faculty of Medicine, in 2011. During her medical training, she gained international clinical experience by serving as an observer at Harvard Medical School – Boston Children’s Hospital.
She completed her residency in Internal Medicine at Bezmialem Vakıf University; during her residency, she served as a visiting physician at the Cleveland Clinic (USA) and the University of Basel (Switzerland).
She completed her sub-specialty training in Medical Oncology in 2022; that same year, she served as an observer physician at the Breast Cancer Unit of the University of Piemonte Orientale in Italy. She attained the title of Associate Professor of Medical Oncology in 2023. Between 2023 and 2025, she served as the Clinical Lead at the Medical Oncology Clinic of Şişli Etfal Training and Research Hospital.
As of April 2025, she practices at Medipol Acıbadem Regional Hospital, focusing on the diagnosis and treatment of solid tumors—particularly breast cancer, lung cancer, gastrointestinal system cancers (colorectal, gastric, pancreatic), gynecological cancers, and genitourinary system cancers. Her clinical approach adopts personalized and multidisciplinary treatment strategies based on molecular oncology.
She has numerous scientific publications in national and international peer-reviewed journals and possesses academic and clinical experience both domestically and abroad. She aims to provide high-quality, patient-centered oncological care based on current scientific data.
She has an advanced command of English and German.
Experiences
2016
Bezmialem Vakif University
2019
Taksim Training And Research Hospital
2022
Bezmialem Vakif University
Hamidiye Etfal Training And Research Hospital
Educations
2022
Bezmialem Vakıf University, Medical Oncology
2016
Bezmialem Vakıf University, Internal Medicine
2011
Istanbul University, Faculty of Medicine
2005
Anadolu University, Health Management
Publications
1. Yasin AI, Uluganyan M, Isleyen ZS, Topcu A, Shbair AT, Simsek M, Besiroglu M, Ersoy YE, Türk HM, Seker M. Cardiac safety of ribociclib evaluated with 24-hour rhythm Holter electrocardiogram. Support Care Cancer. 2024 Jul 8;32(8):492. doi: 10.1007/s00520-024-08702-0. PMID: 38976108; PMCID: PMC11230965.
2. Yasin AI, Aydin SG, Sümbül B, Koral L, Şimşek M, Geredeli Ç, Öztürk A, Perkin P, Demirtaş D, Erdemoglu E, Hacıbekiroglu İ, Çakır E, Tanrıkulu E, Çoban E, Ozcelik M, Çelik S, Teker F, Aksoy A, Fırat ST, Tekin Ö, Kalkan Z, Türken O, Oven BB, Dane F, Bilici A, Isıkdogan A, Seker M, Türk HM, Gümüş M. Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study. Future Oncol. 2022 Jan 27:10.2217/fon-2021-1248. doi: 10.2217/fon-2021-1248. PMID: 35081732; PMCID: PMC8793921.
3. Yasin AI, Topcu A, Akuc MN, Türk HM, Soysal P. A comparison of anticholinergic burden in older patients with and without cancer. Future Oncol. 2021 Dec;17(36):5067-5075. doi: 10.2217/fon-2021-0469. Epub 2021 Oct 27. PMID: 34704458.
4. Yasin AI, Topcu A, Shbair AT, Isleyen ZS, Ozturk A, Besiroglu M, Türk HM. Anxiety levels of breast cancer patients in Turkey during the COVID-19 pandemic. Future Oncol. 2021 Sep;17(25):3373-3381. doi: 10.2217/fon-2020-1265. Epub 2021 Jul 22. PMID: 34291649; PMCID: PMC8297541.
5. Topcu A, Yasin AI, Besiroglu M, Sucuoglu Isleyen Z, Alaca Topcu Z, Simsek M, Turk HM, Seker M, Soysal P. Prevalence and co-incidence of geriatric syndromes according to the ECOG performance status in older cancer patients. Front Med (Lausanne). 2024 Feb 19;11:1331246. doi: 10.3389/fmed.2024.1331246. PMID: 38439897; PMCID: PMC10910106.
6. Hamdard J, Bilici A, Sakin A, Kahraman S, Yasin AI, Kalaci E, Gokmen I, Acikgoz O, Kutlu Y, Sendur MAN, Olmez OF, Seker M. Characteristic features and prognostic factors in gastric cancer patients with bone metastases: multicenter experience. J Chemother. 2024 May 27:1-10. doi: 10.1080/1120009X.2024.2358458. Epub ahead of print. PMID: 38803194.
7. Dülgar Ö, Türker S, Başaran G, Araz M, Sümbül AT, Çağlayan D, Gümüşay Ö, Biter S, Konca A, Özen M, Demir H, Özdemir M, Karataş F, Şahin E, Çavdar E, Yasin Aİ, Yaşar A, Derin S, Pehlivan M, Üyetürk Ü, Özdemir Ö, Kayıkçıoğlu E, Ak N, Şakalar T, Sakin A, Büyükşimşek M, Ay S, Ertürk İ, Akbaş S, Bir Yücel K, Gümüş M. Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter study. J Chemother. 2024 Jun 21:1-7. doi: 10.1080/1120009X.2024.2366683. Epub ahead of print. PMID: 38904164.
8. Ocak B, Sahin AB, Ertürk I, Korkmaz M, Erdem D, Cakıroglu U, Karaca M, Dirican A, Olmez OF, Goktas Aydın S, Gökyer A, Kücükarda A, Gülmez A, Yumuk PF, Demircan NC, Oyman A, Sakalar T, Karatas F, Demir H, Yasin AI, Deligonul A, Dakiki B, Goktug MR, Avcı O, Tacar SY, Turhal NS, Deniz GI, Kacan T, Cubukcu E, Evrensel T. Can Cytoreductive Nephrectomy Improve Outcomes of Nivolumab Treatment in Patients with Metastatic Clear-Cell Renal Carcinoma? Curr Oncol. 2024 Sep 4;31(9):5195-5205. doi: 10.3390/curroncol31090384. PMID: 39330012; PMCID: PMC11431784.
9. Simsek M, Yasin AI, Besiroglu M, Topcu A, Sucuoglu Isleyen Z, Seker M, Turk HM. The efficacy of BNT162b2 (Pfizer-BioNTech) and CoronaVac vaccines in patients with cancer. J Med Virol. 2022 Sep;94(9):4138-4143. doi: 10.1002/jmv.27835. Epub 2022 May 14. PMID:35513241; PMCID: PMC9348062.
10. Dülgar Ö, Öven BB, Atcı MM, Arıkan R, Ay S, Ayhan M, Selvi O, Ozyukseler DT, Bayram E,Özcan E, Yasin Aİ, Gümüş M. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy? Expert Rev Anticancer Ther. 2022 Jul;22(7):773-780. doi:10.1080/14737140.2022.2076670. Epub 2022 Jun 1. PMID: 35543015.
11. Okcu O, Öztürk SD, Öztürk Ç, Şen B, Yasin Aİ, Bedir R. Tumor-infiltrating lymphocytes(TILs)/volume and prognosis: The value of TILs for survival in HER2 and TN breast cancer patients treated with chemotherapy. Ann Diagn Pathol. 2022 Feb 24;58:151930.doi: 10.1016/j.anndiagpath.2022.151930. Epub ahead of print. PMID: 35245821.
12. Gultekin MA, Peker AA, Oktay AB, Turk HM, Cesme DH, Shbair ATM, Yilmaz TF, Kaya A, Yasin AI, Seker M, Mayadagli A, Alkan A. Differentiation of lung and breast cancer brain metastases: Comparison of texture analysis and deep convolutional neural networks. J Clin Ultrasound. 2023 Nov-Dec;51(9):1579-1586. doi: 10.1002/jcu.23558. Epub 2023 Sep 9. PMID: 37688435.
13. Sucuoglu Isleyen Z, Besiroglu M, Yasin AI, Simsek M, Topcu A, Smith L, Akagunduz B, Turk HM, Soysal P. The risk of malnutrition and its clinical implications in older patients with cancer. Aging Clin Exp Res. 2023 Nov;35(11):2675-2683. doi: 10.1007/s40520-023-02538-0. Epub 2023 Aug 29. PMID: 37644257.
14. Topcu A, Yurtsever I, Isleyen ZS, Besiroglu M, Yasin AI, Topcu ZA, Shbair AT, Toluk O, Simsek M, Seker M, Turk HM. The correlation between skeletal muscle index and anxiety in patients with lung cancer on the first day of chemotherapy. Future Oncol. 2023 May;19(16):1139-1149. doi: 10.2217/fon-2022-1200. Epub 2023 Jun 27. PMID: 37367530.
15. Topcu A, Ozturk A, Yurtsever I, Besiroglu M, Yasin AI, Turk HM, Seker M. The effect of sarcopenia on erlotinib therapy in patients with metastatic lung adenocarcinoma. Bosn J Basic Med Sci. 2022 Oct 23;22(6):982-991. doi: 10.17305/bjbms.2022.7147. PMID: 35575465; PMCID: PMC9589317.
16. Simsek M, Besiroglu M, Akcakaya A, Topcu A, Yasin AI, Isleyen ZS, Seker M, Turk HM. Local interventions for colorectal cancer metastases to liver and lung. Ir J Med Sci. 2023 Dec;192(6):2635-2641. doi: 10.1007/s11845-023-03340-7. Epub 2023 Mar 17. PMID: 36929352.
17. Besiroglu M, Shbair AT, Yasin AI, Topcu A, Turk HM, Demir T. Systemic Inflammatory Markers for Prediction of Bevacizumab Benefit in Glioblastoma Multiforme. J Coll Physicians Surg Pak. 2021 Jan;31(1):39-44. doi: 10.29271/jcpsp.2021.01.39. PMID: 33546531.
18. Peker AA, Toprak H, Yasin AI, Aydin M. Uncommon Testicular Germ Cell Tumor Thrombus in Azygos Vein Detected by FDG PET/CT. Clin Nucl Med. 2021 Jul 1;46(7):e347-e348. doi: 10.1097/RLU.0000000000003588. PMID: 33782290.
19. Topcu A, Atci MM, Secmeler S, Besiroglu M, Ayhan M, Ozkan M, Bozkurt O, Urakci Z, Ay S, Geredeli C, Yasin AI, Turk HM. Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer. Future Oncol. 2021 Nov;17(31):4157-4169. doi: 10.2217/fon-2021-0398. Epub 2021 Jul 29. PMID: 34323116.
20. Besiroglu M, Demir T, Shbair ATM, Yasin AI, Topcu A, Turk HM. Is the Duration of Temozolomide Predictive for Sequential Bevacizumab Treatment Responses in the Glioblastoma Multiforme Cancer Setting? J Coll Physicians Surg Pak. 2021 Aug;31(8):932-936. doi: 10.29271/jcpsp.2021.08.932. PMID: 34320710.
21. Topcu A, Yasin AI, Shbair AT, Besiroglu M, Simsek M, Sucuoglu Z, Yurtsever I, Gucin Z, Seker M, Turk HM. A case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer. J Oncol Pharm Pract. 2021 Jun 24:10781552211027931. doi: 10.1177/10781552211027931. Epub ahead of print. PMID: 34162247.
22. Oruç Z, Kaplan MA, Karaağaç M, Özyurt N, Tatlı AM, Kaya AO, Menekşe S, Kut E, Koca S, Sever ÖN, Yasin İ, Ebinç S, Zeynelgil E, Sakin A, Turhal NS, Isikdogan A. Efficacy and tolerability of current treatments for hormone-refractory prostate cancer patients with visceral metastases. Future Oncol. 2021 May;17(13):1611-1624. doi: 10.2217/fon-2020-1032. Epub 2021 Feb 26. PMID: 33631986.
23. Shbair AT, Yasin AI, Topçu A, Coban G, Uzunoglu GD, Şimşek M. Metastatic Breast Carcinoma Mimicking Urothelial Carcinoma. Int J Surg Pathol. 2021 Dec 27:10668969211067923. doi: 10.1177/10668969211067923. Epub ahead of print. PMID: 34955060.
24. Seker M, Isen HC, Çevirme N, Aydın S, Bilici A, Bulut H, Yasin AI, Coban E, Demir T, Aliyev A, Kocyigit A, Turk HM. Role of Urotensin-2 in 5-Fluorouracil-Related Arterial Vasoconstriction in Cancer Patients. Oncol Res Treat. 2018;41(9):545-549. doi: 10.1159/000490120. Epub 2018 Aug 20. PMID: 30121640.